EMAIL DETAILS

Hunter;


This is Wills response. I will wait and hear from you on how you might want to talk to Will. I propose doing an intro by email and you two can schedule a phone conversation that way it's confidential. Let me know? Best; H


Dear Henry,
As always, I'm available to help you and yours. I would be happy to see how I can help Beau. One thing that comes to mind: do you know if there is any tumor specimen that was removed that can be (or has already been) sent to a group like FoundationOne for genetic profiling? This is the basis for the “precision medicine” that was announced nationally. Regardless of a tumor's organ of origin, and regardless of current treatment guidelines based on the best available large scale clinical trials (often requiring the scale of investment only possible by pharma; and hence, constrained by FDA requirement) - the detection of gene mutations or over expressions is now leading us to re-think how we could select targeted therapies that are already available though may not be approved for a specific tumor type. In other words, if we can find the target, and there is a drug, we are now thinking of sending in the drug, regardless of indication, to hit the target. Hence, precision medicine. While the large scale guideline efforts are still framing oncology practice, the need for more tailored treatments based on an individual patient's specific situation is clearly the future. Why not look into this now?

Let me know how I can help.

Best,

Wil